Search results

In April 15, 1953, Australia entered the nuclear science arena, when the Atomic Energy Act came into effect. The Australian Atomic Energy Commission (AAEC) followed and in 1987 the AAEC evolved into the Australian Nuclear Science and Technology Organisation (ANSTO) as it’s known today.

Developed by ANSTO’s predecessor the Australian Atomic Energy Commission (known as the AAEC) in the late 1960s, the Technetium-99m Generator revolutionised nuclear medicine imaging in Australia by enabling imaging procedures to be performed not only in major capital cities but throughout regional and rural Australia.

Congress marks watershed moment for nuclear medicine and ANSTO

Consultant appointed to consider a variety of financial, manufacture and import options.

ANSTO will make an application to the independent nuclear regulator, ARPANSA, to vary its license for its Interim Waste Store. The original operating license was approved in 2015, enabling the facility to hold what is called a TN-81 cask of intermediate-level radioactive waste that was safely repatriated from France in 2015.

ANSTO has safely managed its radioactive waste for over 60 years. Waste is managed in accordance with national and international standards.

On the 9th of December 2022, the Minister for Industry, Science and Technology provided his Statement of Expectations to ANSTO.

ANSTO is a highly regulated organisation. Our governance system and processes provide critical guidance to effectively manage ANSTO’s activities. This section outlines the processes and systems that are in place to provide assurance to Government, our stakeholders and the community that we are working within our regulated and mandated requirements.

Explore ANSTO's range of publications and reports available for the public.

Read about an ANSTO scientist and their work to prepare for a school project or interview.

A targeted radioactive infusion that is a game-changer in late-stage prostate cancer can also dramatically improve outcomes for patients in earlier stages of this disease, a Peter Mac-led study has shown.

The IAEA is providing $1.3m over four years to implement a new, Australian-led patient-care project for the Asia and Pacific region

ANSTO part of consortium funded by Federal Government to develop new radioimmunological drugs.